# Andel

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/andel

- Industry: Healthcare IT
- Headquarters: New York, US
- Website: www.andel.org
- Total disclosed funding: $4.5M
- Latest round: Seed (Oct 20, 2025)
- Investors on record: 7

## About

Andel Co-op, Inc., based in the US, operates as a cooperative employee platform focused on enhancing drug affordability through streamlined access to pharmaceuticals, particularly GLP-1 medications, benefiting both employers and employees.Founded in 2025, Andel is dedicated to improving healthcare access through its cooperative model. The company has not undergone notable pivots in its strategy since its inception. It is headquartered in New York, US. The founder's background is not specified, and there are no references to previous companies founded by the individual. In its most recent funding round in October 2025, Andel raised USD 4.5 mn from investors including Bertelsmann Investments, City Light Capital, Houghton Street Ventures, Lightbank, Seedcamp, SemperVirens, and Springboard Health Angels, marking the total amount raised at USD 4.5 mn.Andel offers a cooperative employee platform that enhances drug affordability through access to GLP-1 medications and other pharmaceuticals. Their intuitive application simplifies the prescription verification and delivery process, allowing employees to obtain medications prescribed by healthcare providers efficiently. This service alleviates the financial burden of high medication costs, supporting employee health. The company serves national employers and health plans aiming to improve their pharmacy benefits while managing costs, with a platform designed for seamless integration into existing benefits cycles across various U.S. markets, with potential for future international expansion.Andel's revenue model is centered on providing pharmacy benefit solutions, particularly covering GLP-1 medications. Revenue is generated through partnerships with employers and health plans, integrating their platform into existing pharmacy benefits systems. The business operates on a subscription basis, where clients pay for access to the service while employees benefit from reduced costs on essential medications. Pricing structures are customized based on negotiations with each client, reflecting their specific needs and workforce size, ultimately aiming to create cost savings for both employers and employees.In October 2025, Andel raised USD 4.5 mn in venture funding, which will be utilized to enhance its platform for employer-backed drug access, develop related technology, and expand its market reach. The company is focused on launching new products aimed at further improving medication accessibility and affordability. Plans for geographic expansion are on the horizon, targeting specific new markets to be detailed in the near future. The funding will support these growth initiatives, underlining Andel's commitment to broadening its impact in the healthcare sector.

## Funding rounds

- Seed, Oct 20, 2025, $4.5M — City Light Capital, Seedcamp, Lightbank, SemperVirens, Houghton Street Ventures, Bertelsmann Investments, Springboard Health Angels

## Investors

- City Light Capital (https://capitalatlas.ai/funds/city-light-capital) — Seed
- Seedcamp (https://capitalatlas.ai/funds/seedcamp) — Seed
- Lightbank (https://capitalatlas.ai/funds/lightbank) — Seed
- SemperVirens (https://capitalatlas.ai/funds/sempervirens) — Seed
- Houghton Street Ventures (https://capitalatlas.ai/funds/houghton-street-ventures) — Seed
- Bertelsmann Investments (https://capitalatlas.ai/funds/bertelsmann-investments) — Seed
- Springboard Health Angels — Seed